AbbVie 3Q Revenues: $5.0 billion (+8%) 3Q Earnings: $506 million (-48%) YTD Revenues: $14.5 billion (+6%) YTD Earnings: $2.6 billion (-14%) Comments: HUMIRA sales increased 18% to $3.3 billion in the quarter. Kaletra sales were $256 million, up 8%. Synthroid sales were up 24% to $200 million. Creon sales were up 48% to $148 million. Synagis sales were up 12% to $109 million and Duodopa sales were $56 million, up 20%. AndroGel sales were down 7% to $232 million. Dyslipidemia sales were down ...